CN Patent

CN117466901A — 哌嗪酰胺衍生物的晶型及其制备方法和用途

Assigned to Zhejiang Hisun Pharmaceutical Co Ltd · Expires 2024-01-30 · 2y expired

What this patent protects

本发明涉及哌嗪酰胺衍生物的晶型及其制备方法和用途，具体涉及式I化合物的晶型A、B、C、D、E及其制备方法、药物组合物和用途，属于化学制药领域，解决了式I化合物的无定形形式存在的颗粒度小、流动性差、稳定性差等问题。本发明制备的晶型及其药物组合物可用于制备治疗癌症的疾病的药物。

USPTO Abstract

本发明涉及哌嗪酰胺衍生物的晶型及其制备方法和用途，具体涉及式I化合物的晶型A、B、C、D、E及其制备方法、药物组合物和用途，属于化学制药领域，解决了式I化合物的无定形形式存在的颗粒度小、流动性差、稳定性差等问题。本发明制备的晶型及其药物组合物可用于制备治疗癌症的疾病的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN117466901A
Jurisdiction
CN
Classification
—
Expires
2024-01-30
Drug substance claim
No
Drug product claim
No
Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.